JAK2 phosphorylates histone H3Y41 and excludes HP1α from chromatin

Nature

Volumn 461, Issue 7265, 2009, Pages 819-822

  Dawson, Mark A ^a,b   Bannister, Andrew J ^c   Göttgens, Berthold ^a   Foster, Samuel D ^a   Bartke, Till ^c   Green, Anthony R ^a,b   Kouzarides, Tony ^c  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HETEROCHROMATIN PROTEIN 1; HISTONE H3; JANUS KINASE 2; STAT5 PROTEIN;

ABNORMALITY; CHROMOSOME; CYTOLOGY; CYTOPLASM; GENE EXPRESSION; HEMATOLOGY; HOMINID; PROTEIN;

ARTICLE; CELL LINE; CHROMATIN; GENE MUTATION; HEMATOPOIESIS; HEMATOPOIETIC CELL; HUMAN; LEUKEMIA; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; BINDING SITES; CELL LINE; CELL NUCLEUS; CHROMATIN; CHROMOSOMAL PROTEINS, NON-HISTONE; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HEMATOPOIESIS; HEMATOPOIETIC STEM CELLS; HISTONES; HUMANS; JANUS KINASE 2; LEUKEMIA; METALLOPROTEINS; MICE; ONCOGENES; PHOSPHORYLATION; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; SIGNAL TRANSDUCTION; TYROSINE;

EID: 70349975711     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature08448     Document Type: Article

References (33)

1. Campbell, P. J. & Green, A. R. The myeloproliferative disorders. N. Engl. J. Med. 355, 2452-2466 (2006).
2. Levine, R. L., Pardanani, A., Tefferi, A. & Gilliland, D. G. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nature Rev. Cancer 7, 673-683 (2007).
3. Scott, L. M. et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N. Engl. J. Med. 356, 459-468 (2007).
4. Lacronique, V. et al. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science 278, 1309-1312 (1997).
5. Bercovich, D. et al. Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down?s syndrome. Lancet 372, 1484-1492 (2008).
6. Mullighan, C. G. et al. JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proc. Natl Acad. Sci. USA 106, 9414-9418 (2009).
7. McCormack, M. P. & Rabbitts, T. H. Activation of the T-cell oncogene LMO2 after gene therapy for X-linked severe combined immunodeficiency. N. Engl. J. Med. 350, 913-922 (2004).
8. Neubauer, H. et al. Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis. Cell 93, 397-409 (1998).
9. Yamada, Y. et al. The T cell leukemia LIM protein Lmo2 is necessary for adult mouse hematopoiesis. Proc. Natl Acad. Sci. USA 95, 3890-3895 (1998).
10. Walz, C. et al. Activated Jak2 with the V617F point mutation promotes G1/S phase transition. J. Biol. Chem. 281, 18177-18183 (2006).
11. Zhao, R. et al. Inhibition of the Bcl-xL deamidation pathway in myeloproliferative disorders. N. Engl. J. Med. 359, 2778-2789 (2008).
12. Plo, I. et al. JAK2 stimulates homologous recombination and genetic instability: potential implication in the heterogeneity of myeloproliferative disorders. Blood 112, 1402-1412 (2008).
13. Shi, S. et al. JAK signaling globally counteracts heterochromatic gene silencing. Nature Genet. 38, 1071-1076 (2006).
14. Quentmeier, H., MacLeod, R. A., Zaborski, M. & Drexler, H. G. JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders. Leukemia 20, 471-476 (2006).
15. Watling, D. et al. Complementation by the protein tyrosine kinase JAK2 of a mutant cell line defective in the interferon-c signal transduction pathway. Nature 366, 166-170 (1993).
16. Pardanani, A. et al. TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations. Leukemia 21, 1658-1668 (2007).
17. Xie, S. et al. Involvement of Jak2 tyrosine phosphorylation in Bcr-Abl transformation. Oncogene 20, 6188-6195 (2001).
18. Squires, M. S. et al. AT9283, a potent inhibitor of JAK2, is active in JAK2 V617F myeloproliferative disease models. Blood 110, Abstract 3537 (2007).
19. Bannister, A. J. et al. Selective recognition of methylated lysine 9 on histone H3 by the HP1 chromo domain. Nature 410, 120-124 (2001).
20. Lachner, M., O?Carroll, D., Rea, S., Mechtler, K. & Jenuwein, T. Methylation of histone H3 lysine 9 creates a binding site for HP1 proteins. Nature 410, 116-120 (2001).
21. Wood, A. D. et al. Id1 promotes expansion and survival of primary erythroid cells and is a target of JAK2V617F-STAT5 signalling. Blood 114, 1820-1830 (2009).
22. Donaldson, I. J., Chapman, M. & Gottgens, B. TFBScluster: a resource for the characterization of transcriptional regulatory networks. Bioinformatics 21, 3058-3059 (2005).
23. Ma, A. C., Ward, A. C., Liang, R. & Leung, A. Y. The role of jak2a in zebrafish hematopoiesis. Blood 110, 1824-1830 (2007).
24. Ferreira, H., Somers, J., Webster, R., Flaus, A. & Owen-Hughes, T. Histone tails and the H3 aN helix regulate nucleosome mobility and stability. Mol. Cell. Biol. 27, 4037-4048 (2007).
25. Cummings, W. J. et al. Chromatin structure regulates gene conversion. PLoS Biol. 5, e246 (2007).
26. Panteleeva, I. et al. HP1a guides neuronal fate by timing E2F-targeted genes silencing during terminal differentiation. EMBO J. 26, 3616-3628 (2007).
27. Yamagishi, Y., Sakuno, T., Shimura, M. & Watanabe, Y. Heterochromatin links to centromeric protection by recruiting shugoshin. Nature 455, 251-255 (2008).
28. Osborn, L., Kunkel, S. & Nabel, G. J. Tumor necrosis factor a and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor kB. Proc. Natl Acad. Sci. USA 86, 2336-2340 (1989).
29. Dyer, P. N. et al. Reconstitution of nucleosome core particles from recombinant histones and DNA. Methods Enzymol. 375, 23-44 (2004).
30. Bannister, A. J. & Kouzarides, T. The CBP co-activator is a histone acetyltransferase. Nature 384, 641-643 (1996).
31. Krude, T. Mimosine arrests proliferating human cells before onset of DNA replication in a dose-dependent manner. Exp. Cell Res. 247, 148-159 (1999).
32. Krude, T. Initiation of human DNA replication in vitro using nuclei from cells arrested at an initiation-competent state. J. Biol. Chem. 275, 13699-13707 (2000).
33. Nielsen, S. J. et al. Rb targets histone H3 methylation and HP1 to promoters. Nature 412, 561-565 (2001).